MoonLake Immunotherapeutics
MLTX
$13.35
$0.836.63%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -210.50M | -176.16M | -145.21M | -118.94M | -80.77M |
| Total Depreciation and Amortization | 3.17M | 2.77M | 2.37M | 2.32M | 1.38M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.67M | 4.14M | 4.36M | 3.81M | 5.23M |
| Change in Net Operating Assets | 15.97M | 2.82M | -1.31M | -3.78M | -6.30M |
| Cash from Operations | -185.69M | -166.42M | -139.78M | -116.59M | -80.46M |
| Capital Expenditure | -210.60K | -342.60K | -342.60K | -519.60K | -628.60K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 85.78M | 55.79M | -120.20M | -205.08M | 59.23M |
| Cash from Investing | 85.57M | 55.45M | -120.55M | -205.60M | 58.60M |
| Total Debt Issued | 73.02M | 73.02M | 73.02M | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 730.70K | 341.70K | 341.70K | 52.78M | 83.80M |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 92.00K | 92.00K | -1.47M | -4.22M |
| Cash from Financing | 73.75M | 73.46M | 73.46M | 51.31M | 79.58M |
| Foreign Exchange rate Adjustments | 1.44M | 1.40M | -6.20K | 127.80K | -231.30K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -24.92M | -36.11M | -186.88M | -270.74M | 57.49M |